Overview

A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

Status:
Terminated
Trial end date:
2020-03-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.
Phase:
Phase 1
Details
Lead Sponsor:
Indalo Therapeutics, Inc.